Subacute Cutaneous Lupus Erythematosus Induced by Nifedipine

2003 ◽  
Vol 7 (3) ◽  
pp. 243-246 ◽  
Author(s):  
Emanuela Gubinelli ◽  
Barbara Cocuroccia ◽  
Giampiero Girolomoni
Keyword(s):  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Skin Lesions ◽  
Channel Blockers ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Rapid Improvement ◽  
Drug Induced ◽  
Dermoepidermal Junction ◽  
Antihistone Antibody ◽  
Cutaneous Lupus

Background: Subacute cutaneous lupus erythematosus (SCLE) has been reported to be associated with the use of several drugs, including thiazides, terbinafine, and, rarely, calcium channel blockers. Objective: A case of SCLE induced by nifedipine is presented. Methods and Results: A 48-year-old white woman developed a papulosquamous and annular eruption in sun-exposed areas during the summer. The patient was taking nifedipine for essential hypertension for four years. Serology showed the presence of antinuclear and anti-Ro/SSA as well as antihistone antibodies. Histopathologic and immunopathologic (granular IgM deposits at the dermoepidermal junction) findings confirmed the diagnosis of SCLE. Nifedipine discontinuation led to rapid improvement with almost complete resolution of skin lesions in one month in the absence of active treatment. Reduction of antinuclear, anti-Ro/SSA, and antihistone antibody levels was documented after six months. Conclusion: Nifedipine can cause SCLE after a long period of administration. Antihistone antibodies may be associated with drug-induced SCLE.

scholarly journals Drug-induced subacute cutaneous lupus erythematosus caused by amlodipine

2018 ◽  
Vol 105 (2) ◽  
pp. 298-306
Author(s):  
Agata Kozłowska ◽  
Zdzisław Woźniak ◽  
Joanna Maj ◽  
Rafał Białynicki-Birula
Keyword(s):  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
Cutaneous Lupus

scholarly journals Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma

2019 ◽  
Vol 12 (11) ◽  
pp. e230558 ◽  
Author(s):  
Jesse Hirner
Keyword(s):  
Proton Pump Inhibitor ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Laboratory Evaluation ◽  
Topical Steroids ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
Dermatology Clinic ◽  
Common Causes ◽  
Cutaneous Lupus

A 52-year-old man was referred to our dermatology clinic for a diagnosis of melanoma. At the time, his melanoma was excised he developed an annular, polycyclic, scaling eruption consistent with subacute cutaneous lupus erythematosus (SCLE). Skin biopsy and laboratory evaluation confirmed this diagnosis. The patient had been using pantoprazole for gastro-oesophageal reflux disease for the last 3 years. The patient’s melanoma was treated surgically, and his SCLE was treated with topical steroids and hydroxychloroquine. His SCLE cleared rapidly, his steroids and hydroxychloroquine were stopped and he remains free of SCLE off of treatment. The parallel course of the patient’s SCLE and melanoma prompted consideration of SCLE as paraneoplastic to melanoma in this case. The clinical picture was complicated by the patient’s use of a proton pump inhibitor, which are common causes of drug-induced SCLE. To our knowledge, this is the first reported case of possible paraneoplastic SCLE associated with melanoma.

scholarly journals Capecitabine-Induced Subacute Cutaneous Lupus Erythematosus in a Patient with Systemic Lupus Erythematosus

2018 ◽  
Vol 2 (1) ◽  
pp. 59-63
Author(s):  
Alyx Rosen ◽  
Evan Darwin ◽  
Jennifer N Choi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Metastatic Breast ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Increased Risk ◽  
History Of ◽  
Cutaneous Lupus

Capecitabine is a fluoropyrimidine chemotherapy prodrug of 5-fluorouracil (5-FU) used in the treatment of metastatic breast and colorectal cancers. Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is a rare side effect of capecitabine therapy, with eight cases previously reported. We report a case of DI-SCLE in a patient with a documented history of systemic lupus erythematosus (SLE). This is the second documented case of DI-SCLE in a patient with a past medical history of SLE, and provides evidence that there may be an increased risk of DI-SCLE in these patients. Further research should examine whether patients with SLE are at greater risk for this adverse event. 

Sign in / Sign up

Export Citation Format

Share Document